Does BROLUCIZUMAB-DBLL Cause Choroidal neovascularisation? 38 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 38 reports of Choroidal neovascularisation have been filed in association with BROLUCIZUMAB-DBLL. This represents 1.4% of all adverse event reports for BROLUCIZUMAB-DBLL.
38
Reports of Choroidal neovascularisation with BROLUCIZUMAB-DBLL
1.4%
of all BROLUCIZUMAB-DBLL reports
0
Deaths
1
Hospitalizations
How Dangerous Is Choroidal neovascularisation From BROLUCIZUMAB-DBLL?
Of the 38 reports, 1 (2.6%) required hospitalization.
Is Choroidal neovascularisation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BROLUCIZUMAB-DBLL. However, 38 reports have been filed with the FAERS database.
What Other Side Effects Does BROLUCIZUMAB-DBLL Cause?
Vitreous floaters (479)
Visual impairment (446)
Vision blurred (416)
Eye inflammation (387)
Visual acuity reduced (365)
Retinal vasculitis (323)
Uveitis (305)
Vitritis (284)
Eye pain (234)
Vitreous opacities (205)
What Other Drugs Cause Choroidal neovascularisation?
RANIBIZUMAB (195)
PEGCETACOPLAN (52)
AFLIBERCEPT (47)
VERTEPORFIN (47)
BEVACIZUMAB (38)
PENTOSAN POLYSULFATE (17)
PREDNISONE (10)
SILDENAFIL (10)
LUCENTIS (9)
AVACINCAPTAD PEGOL (7)
Which BROLUCIZUMAB-DBLL Alternatives Have Lower Choroidal neovascularisation Risk?
BROLUCIZUMAB-DBLL vs BROMAZEPAM
BROLUCIZUMAB-DBLL vs BROMFENAC
BROLUCIZUMAB-DBLL vs BROMHEXINE
BROLUCIZUMAB-DBLL vs BROMOCRIPTINE
BROLUCIZUMAB-DBLL vs BROTIZOLAM